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INTRODUCTION
Chemotherapy is a critical approach in the treatment 
of advanced or recurrent endometrial cancer. The use of 
chemotherapy is now the standard treatment for women 
with early-stage disease. However, there are no agents 
approved by the US Food and Drug Administration for 
the metastatic setting of endometrial cancer, which has a 
very low chance to be treated with success. Due to the 
great expectation on novel targeting agents in advanced 
endometrial cancer, new drugs against specific molecular 
pathways with particular focus on PI3KCA/AKT/mTOR 
axis are emerging as promising treatments for endometrial 
cancer with aggressive phenotype [1]. The very issue 
is the lack of progress in cancer treatment due to the 
heterogeneity and the genetic complexity of many tumours 
leading to an urgent knowledge of the molecular profile 
of an individual’s tumour to guide appropriate treatment 
selection.
We have read with enthusiasm the article by 
Slomovitz et al published in Journal of Clinical Oncology 
on January 26, 2015 where it was reported the increased 
clinical benefit rate with the combination of letrozole 
and everolimus in women with recurrent endometrial 
cancer along with a manageable toxicity [2]. Moreover, 
patients with endometriod histotype carrying the CTNNB1 
mutations underwent to a good response to treatment. 
On the counterpart the serous histology did not respond 
with the same rate to mTOR inhibition; moreover they 
have not identified based on the molecular analysis 
they performed a possible responsive-subtype of the 
serous cancer. The Cancer Genome Atlas has led to the 
molecular reclassification of endometrial cancer. These 
genomic advances are determinant for the proper selection 
of the adequate therapy in the future of the patient care. 
In the genomic era, clinicians and molecular oncologists 
should invest their efforts in finding “druggable” targets 
for the available drugs on the market. In our clinical 
experience, letrozole alone is already able to modulate 
the mTOR axis in breast cancer [3] suggesting its 
use also in other endocrine- related cancer such as 
estrogen receptors positive endometrial cancer. In our 
experience, the molecular analysis of the primary tumor 
or of the metastasis from endometrial cancer showed 
low percentage rate of mutations of PIK3CA and KRAS 
according on what reported by Slomovitz et al [2].  
As previously reported that from the minimal genetic 
variations in the PI3K or FGFR pathways or CCND1, 
derives the most benefit from EVE based-therapy (HR 
= 0.27 vs 0.40 for the full NGS population) [4], in three 
serous endometrial cancers not responsive to conventional 
therapies, we applied for further molecular analysis, a part 
KRAS, PIK3CA and proliferation related genes, with 
particular regards to the staining of the estrogen receptor 
and FGFR2 FISH-based evaluation (Figure 1 A e B). The 
combination of 1gr medroxyprogesterone acetate daily 
and 10 mg everolimus daily induced stable radiological 
response of the liver metastases and partial radiological 
response in lung metastases during the time course of 
treatment in 2 patients with FGFR2 amplification (Figure 
1 C and D). No response was detected in 1 patient without 
amplification of FGFR signal.  Amplification or mutation 
of fibroblast growth factor receptor (FGFR) has been 
reported in endometrial cancers with a frequency of 10% 
and FGFR2 may represent a novel molecular target for the 
treatment of endometrial cancer [5]. Activation of FGFR 
induces PI3K and AKT activities through recruitment and 
tyrosine phosphorylation of the docking protein Gab1 that 
results in the activation of PI3K [6]. In our FGFR2+ve 
patients, we obtained, accordingly to the mRECIST 
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Criteria, stable disease longer than 12 months in line with 
the positive data from the recent progression free survival 
analysis from the BOLERO-2 trial [7]. These results 
suggest that longer stable disease maybe achieved in the 
absence of a direct alteration in the PI3K/AKT/mTOR 
pathway, even when multiple molecular aberrations are 
present. However, FGFR2 may modulate the PIK3CA/
AKT/mTOR axis perhaps explaining in part the response. 
Slomovitz et reported that only few patients with serous 
endometrial cancer responded to the combination of 
letrozole/everolimus and maybe they were FGFR 1 or 2 
amplified. 
Thus, the combination of everolimus and aromatase 
inhibitors has the change to show some activity in 
the particular subtype of EC as the FGFR2+ve serous 
carcinoma. Tumors with ER expression are dependent 
upon downstream growth factor signaling and may 
respond better with the addition of molecular inhibitors 
based on the proper target selection. Indeed, our reports 
encourage the perspective investigation of combination 
of everolimus along with hormone-therapy in pre-treated 
FGFR2+ recurrent endometrial cancer patients. Specific 
molecular analysis with focus on FGFR signalling in 
serous endometrial cancer is mandatory.
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